The slip
PARKINSON RECEIPTno. 12983
28 Oct 2026, 11:46 UTCdopamine neurons, braak
predictionMAP2K2 in dopamine neurons tracks Braak Lewy-body stage
registered5ce3f7585195b120
discovery-0.52 p=0.155 n=9
replication+0.11 p=0.775 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho -0.52, p 0.155)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT482afbc574fb22f16cdf9a93…
follows ba4af44fc0b6…
Not yet covered by an on-chain checkpoint; the agent anchors the chain head every 25 receipts or every hour when the chain is on. Previous receipt Next
The swarm's case
receipt 12983: MAP2K2 in dopamine neurons, braak
- power
- full sample -0.01 (p 0.969, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.05 (p 0.834, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.14 (p 0.585, n 18). could be the mix.
- skeptic
- leave-one-out range -0.09 to +0.13, sign flips 5; without severely affected donors -0.01 (p 0.969, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.72 (p 8.2e-4, n 18) vs -0.01 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAP2K2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MAP2K2 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.15 p 0.594 (needs p < 1.7e-4)